OBJECTIVE: The purpose of this study was to determine if: 1) insulin-like growth factor binding protein-1 (IGFBP-1) in amniotic fluid (AF) exhibited proteolytic cleavage in cases of intra-amniotic inflammation; and 2) if the matrix metalloproteinases (MMP-3, MMP-8, MMP-9) in AF are associated with the degradation of IGFBP-1 in AF. METHODS: AF samples (n=20) were obtained from preterm gestations with and without intra-amniotic inflammation. The form of IGFBP-1 in AF was assessed by Western blot analysis and AF MMP-8 concentration was measured by ELISA. Densitometric analysis of Western blot was performed and the fragmented/intact IGFBP-1 ratio was calculated. Proteolysis of AF IGFBP-1 by MMPs was evaluated by incubating AF with exogenous human MMP-3, MMP-8 or MMP-9, and by incubating recombinant human IGFBP-1 in AF with and without inflammation. RESULTS: 1) IGFBP-1 was present in AF without inflammation as an intact form; however, the fragmented form was dominant in AF with inflammation; 2) the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation; 3) a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of MMP-8; 4) in-vitro proteolysis experiments showed that AF IGFBP-1 was degraded by exogenous human MMP-3, MMP-8 and MMP-9; 5) recombinant human IGFBP-1 was fragmented in AF with inflammation, but not in AF without inflammation. CONCLUSION: The fragmented form of AF IGFBP-1 was significantly increased in AF with intra-amniotic inflammation, and MMPs produced in AF with intra-amniotic inflammation were associated with the proteolytic change of AF IGFBP-1.
OBJECTIVE: The purpose of this study was to determine if: 1) insulin-like growth factor binding protein-1 (IGFBP-1) in amniotic fluid (AF) exhibited proteolytic cleavage in cases of intra-amniotic inflammation; and 2) if the matrix metalloproteinases (MMP-3, MMP-8, MMP-9) in AF are associated with the degradation of IGFBP-1 in AF. METHODS:AF samples (n=20) were obtained from preterm gestations with and without intra-amniotic inflammation. The form of IGFBP-1 in AF was assessed by Western blot analysis and AFMMP-8 concentration was measured by ELISA. Densitometric analysis of Western blot was performed and the fragmented/intact IGFBP-1 ratio was calculated. Proteolysis of AFIGFBP-1 by MMPs was evaluated by incubating AF with exogenous humanMMP-3, MMP-8 or MMP-9, and by incubating recombinant humanIGFBP-1 in AF with and without inflammation. RESULTS: 1) IGFBP-1 was present in AF without inflammation as an intact form; however, the fragmented form was dominant in AF with inflammation; 2) the ratio of fragmented/intact IGFBP-1 was significantly higher in AF with inflammation than in AF without inflammation; 3) a higher ratio of fragmented/intact IGFBP-1 was associated with a higher concentration of MMP-8; 4) in-vitro proteolysis experiments showed that AFIGFBP-1 was degraded by exogenous humanMMP-3, MMP-8 and MMP-9; 5) recombinant humanIGFBP-1 was fragmented in AF with inflammation, but not in AF without inflammation. CONCLUSION: The fragmented form of AFIGFBP-1 was significantly increased in AF with intra-amniotic inflammation, and MMPs produced in AF with intra-amniotic inflammation were associated with the proteolytic change of AFIGFBP-1.
Authors: Carole S Watson; Peter Bialek; Makoto Anzo; Javad Khosravi; Siu-Pok Yee; Victor K M Han Journal: Endocrinology Date: 2005-11-17 Impact factor: 4.736
Authors: Jonathan L Hecht; Raina N Fichorova; Vanessa F Tang; Elizabeth N Allred; Thomas F McElrath; Alan Leviton Journal: Pediatr Res Date: 2011-01 Impact factor: 3.756
Authors: Emmanuel Bujold; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Francesca Gotsch; Tinnakorn Chaiworapongsa; Ricardo Gomez; Jimmy Espinoza; Edi Vaisbuch; Yeon Mee Kim; Samuel Edwin; Mike Pisano; Beth Allen; Vladimir N Podust; Enrique A Dalmasso; Jennifer Rutherford; Wade Rogers; Allan Moser; Bo Hyun Yoon; Tim Barder Journal: J Matern Fetal Neonatal Med Date: 2008-10
Authors: Andrew D Winters; Roberto Romero; Jonathan M Greenberg; Jose Galaz; Zachary D Shaffer; Valeria Garcia-Flores; David J Kracht; Nardhy Gomez-Lopez; Kevin R Theis Journal: Front Immunol Date: 2022-02-28 Impact factor: 7.561